The R-CHOP regimen consisted of rituximab at a dose of 375 mg per square meter (maximum dose, 750 mg), cyclophosphamide at a dose of 750 mg per square meter, doxorubicin at a dose of 50 mg per square ...
Please provide your email address to receive an email when new articles are posted on . The regimen conferred a 71% complete response rate among older adults with newly diagnosed DLBCL. Median PFS and ...
Although rituximab (R) is commonly used for patients with advanced follicular lymphoma (FL) requiring treatment, the optimal associated chemotherapy regimen has yet to be clarified. The April 20, 2013 ...
Results presented at the 63rd Annual American Society of Hematology Meeting showed that using polatuzumab vedotin instead of vincristine in R-CHOP improved progression-free survival in patients with ...
ATLANTA -- After 15 years as standard of care for previously untreated diffuse large B-cell lymphoma (DLBCL), R-CHOP has fallen to a new, though similar, regimen in a randomized trial. At a median ...
Thomas M. Habermann, MD, is a hematologist with the Mayo Clinic in Rochester, Minnesota. A member of the Lymphoma Research Foundation Scientific Advisory Board, Habermann is well known as the lead ...
Earlier this year, the FDA approved a new frontline option for patients with diffuse large B-cell lymphoma (DLBCL): the antibody-drug conjugate polatuzumab vedotin (Polivy) in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results